Personalized medicine improves the treatment of knee osteoarthritis

Thank you for reading this post, don't forget to subscribe!

Experts point out that advances in precision medicine will cause important changes in the approach to patients with osteoarthritis in the next 10 years. The optimization of clinical data is key to establishing tailored and individualized treatments, depending on the origin and evolution of knee osteoarthritis.

The advances in precision medicine of recent years allow more adjusted strategies to each patient of knee osteoarthritis, depending on the origin and the time of evolution of the illness. This makes it possible to predict their prognosis and adjust the treatment more precisely to each person.

It is one of the conclusions II SER Course of Personalized Medicinecelebrated in a manner virtualIn collaboration with Pfizerwhere different experts have addressed issues such as the Contribution of new technologies to the field of health.

As pointed out by Dr. Francis Castrorheumatologist at the Sagrat Cor University Hospital in Barcelona, “In the field of osteoarthritis, recent studies have shown that, through genotyping techniquesit is possible to identify patients who are in an early stage of the disease, but who present a increased risk of structural progression of knee osteoarthritis«.

In the II SER Courses on Personalized Medicine, issues such as advances in the prognosis of knee osteoarthritis were addressed

“In the field of knee osteoarthritishave been able to describe combinations of biochemical markers in blood and urine that make possible distinguish molecularly groups of patients at risk of disease progression versus those who are not. Another has also been identified molecular signature that identifies a group of patients with systemic inflammationwith the potential to open new fields in drug trials that target inflammation and pain in osteoarthritis”emphasizes the specialist.

“The possibility of predict which patients will progress and which will not It will be a paradigm shift in the design of trials with disease-modifying drugswhich act at the level of cartilage and subchondral bone targets, since the possibility of testing it in the most susceptible patients implies the potential to improve results and efficiency, achieving a more effective therapy and in less timeconcludes Dr. Castro.

The new discoveries with biomarkers will enable the description of subgroups of patients with rheumatic diseases in a more homogeneous way, which results in a maximization of the benefits of treatments and fewer side effects.

The advances in the convergence of omics, the big data clinical and the machine learninglead us to realities, in the next ten years, in which we can design a therapy exactly tailored to a single specific patientsomething that is already happening in other fields of medicine, as explained in the II SER Course of Personalized Medicine.

The importance of reusable and integrable data

The latest recommendations in data management in research focus on data being reusable and integrable with other data, to achieve the construction of large bases.

In this sense, Dr. Diego Benaventerheumatologist at the La Paz University Hospital in Madrid, indicates that “the way to achieving the promises of personalized medicineas the right treatment, at the right time, for the right patient, goes through optimize the use of clinical data, adapt to new research methodologies and implement the conclusions of studies in daily clinical practice».

geriatricrea osteoarthritis of the knee
Advances in precision medicine allow strategies that are more tailored to each patient with knee osteoarthritis

The doctor Diego Benaventerheumatologist La Paz University Hospital in Madridstates that “the development of predictive models in rheumatic pathology based on precise artificial intelligence rheumatologists involved in studies to establish relevant research questions, support data scientists Y critically appraise the results”.

II SER Course of Personalized Medicine

The dialogue center of this new edition of the Courses BE of Personalized Medicine, which has had the help of the pharmaceutical company Pfizer, has revolved around topics such as new technologies in biomarkers, The contribution of omics technologies to personalized medicine in autoimmune diseases Y precision rheumatology in the clinicamong others.

Within this scenario, different experts contributed their knowledge and daily experiences to reach new steps in this sector. like the doctor Francis J WhiteProfessor of Rheumatology at the University of A Coruna and of Rheumatology Service of the University Hospital Complex of A Coruñawhich argues that «it is essential train in this field because it is the near future of Medicine and Rheumatology. The tomorrow of the patients goes through the ability to predict the onset of diseasesthe forecast of them and know what they are the best treatments for eachof individualized form«.

Related Articles

Back to top button